Interest in messenger RNA (mRNA) vaccines has accelerated in recent years, driven largely by the rapid development and strong performance of COVID-19 vaccines built on the platform. Their speed of production, high efficacy and favorable safety profiles have underscored the broader therapeutic potential of mRNA technology.
Beyond infectious diseases, researchers are increasingly exploring mRNA’s role in oncology. Personalized mRNA cancer vaccines are designed to train a patient’s immune system to recognize tumor-specific mutations, known as neoantigens. By targeting these unique markers, the approach aims to direct immune attacks toward cancer cells while minimizing damage to healthy tissue. As the technology advances through clinical trials, oncology nurses are likely to play a growing role in supporting patients receiving these therapies.
Phase 1 Trial Tests Personalized mRNA Vaccine in TNBC
A Phase 1 study published in Nature by Ugur Sahin, MD, and colleagues evaluated the safety, feasibility and immune response of a personalized uridine mRNA-based neoantigen vaccine in patients with triple-negative breast cancer (TNBC). Participants had completed standard treatment, including surgery with or without chemotherapy and radiotherapy.
Fourteen patients received vaccines tailored to the unique mutations identified in their tumors through detailed DNA and RNA sequencing. These patient-specific neoantigens were encoded into RNA fragments and packaged in lipid nanoparticles for intravenous delivery, a system designed to promote efficient uptake by immune cells.
The vaccine was generally well tolerated, with no severe or unexpected adverse events reported. Its RNA–lipoplex formulation was engineered to enhance delivery of neoantigens to immune cells, effectively “teaching” the immune system to detect and attack tumor cells based on subtle mutation patterns.
Durable and Broad T Cell Activation
Immune analyses showed that nearly all participants developed robust T cell responses against their selected neoantigens. Both CD8+ cytotoxic T cells, which directly kill cancer cells, and CD4+ helper T cells, which sustain immune responses, were activated. Many patients generated responses to multiple neoantigens simultaneously, suggesting a broad and diversified immune reaction.
Importantly, neoantigen-specific T cells persisted for years after vaccination. Researchers observed a combination of late-differentiated cytotoxic effector cells, capable of immediate tumor attack, and stem-like memory T cells, which support long-term immune surveillance. In some patients, vaccination generated entirely new T cell responses, while in others it amplified pre-existing immunity. Advanced laboratory tracking confirmed that these T cells recognized mutations specific to each patient’s tumor.
Five-Year Follow-Up Shows Encouraging Outcomes
At a median follow-up of five years, 10 of the 14 patients remained relapse-free. Three experienced disease recurrence, each reflecting a different mechanism of immune evasion.
One patient with BRCA1-mutated bilateral tumors developed a new, independent tumor that was not targeted by the vaccine. Another patient’s recurrent tumor lost major histocompatibility complex (MHC) class I expression, preventing T cells from recognizing cancer cells. A third patient mounted only a weak initial vaccine response, later responded to anti–PD-1 therapy, but ultimately relapsed.
The findings suggest that even in cancers with a moderate mutation burden such as TNBC, personalized neoantigen vaccines can induce durable, multi-targeted immune responses. However, tumor escape mechanisms — including antigen loss, impaired antigen presentation, or development of independent tumor clones — highlight the potential need for combination strategies with other immunotherapies.
Implications for Oncology Nursing Practice
As personalized mRNA vaccines move closer to broader clinical use, oncology nurses will play a central role in patient care. Monitoring for common vaccine-related side effects — such as mild flu-like symptoms, low-grade fever or injection-site reactions — will be essential. Nurses also help patients distinguish between expected immune activation and signs of infection, explaining that temporary fatigue or fever may reflect T cell engagement.
Long-term follow-up is another key component. Coordinating blood draws to assess immune persistence and helping patients understand the significance of sustained T cell activity over months or years are critical aspects of care.
In addition, nurses are often instrumental in discussing complex treatment plans, including combinations of neoantigen vaccines with checkpoint inhibitors. By providing balanced information about potential benefits and risks, they support informed decision-making and may encourage eligible patients to consider participation in clinical trials exploring personalized mRNA-based cancer therapies.
As mRNA technology continues to evolve beyond infectious disease prevention, early-stage data from TNBC trials signal that individualized cancer vaccines could become an important addition to the immunotherapy landscape.
